Interleukin (IL)-33 is a member of the IL-1 family and is able to act cardioprotective.
organisation of cardiac tissue and, as a consequence, in myocardial hypertrophy.
BPs represent another group of drugs targeting the mevalonate (MVA) pathway and are used for the treatment of osteoporosis and other diseases involving bone resorption. 10 BPs also exert beneficial functions in the cardiovascular system: they attenuate cardiac hypertrophy as well as fibrosis and improve endothelial function in hypertensive rats and mice, and cause regression of atherosclerosis. [11] [12] [13] [14] However, the mechanisms underlying the pleiotropic effects of statins and BPs in myocardial tissue remodelling are not yet fully clarified.
IL-33 belongs to the IL-1 family of cytokines. 15 Depending on the experimental model and the pathophysiological context IL-33
can act either pro-or anti-inflammatory. 3, [16] [17] [18] [19] [20] In the heart, IL-33 is believed to be cardioprotective as it was shown to possess antihypertrophic and anti-apoptotic properties in animal models of pressure overload or myocardial infarction, respectively. [21] [22] [23] [24] In this study, we aimed to explore if statins and BPs can influence the expression of IL-33 in human adult cardiac myocytes and fibroblasts, and to reveal the responsible mechanisms. Additionally, we compared IL-33 expression in explanted hearts from statin-treated versus non-statin-treated patients with end-stage HF undergoing heart transplantation.
| MATERIALS AND METHODS

| Reagents
Stock solutions of atorvastatin (kindly provided by Pfizer, Sandwich, UK), fluvastatin (kindly provided by Novartis, Basel, Switzerland), pravastatin (kindly provided by Bristol-Myers-Squibb, Paris, France), lovastatin and simvastatin (kindly provided by Merck Sharpe and Dome, Ballydine, Ireland) were prepared as described. 25 Such stocks were aliquoted and stored at −80°C. Alendronate, ibandronate, MVA, GGPP, FPP, squalene, coenzyme Q10, latrunculin B, and perillic acid were purchased from Sigma (St. Louis, MO, USA). Y-27632
and U-46619 were purchased from Cayman Chemical Company (Ann Arbor, MI, USA).
| Cell culture
Primary HACM and HACF were isolated from myocardial tissue obtained from explanted recipients' hearts after heart transplantation and cultivated as described by our group. 8, 26, 27 For this study, cells were isolated from the hearts of 10 different donors (eight persons >18 years old and two children, mean age 40.5 ± 20.8; six males and four females) suffering from different pathologies (three patients with ischaemic cardiomyopathy, five patients with dilated cardiomyopathy (in one case perinatal), one patient with constrictive pericarditis, and one child with an atrioventricular septal defect).
HACM were isolated from ventricular tissue and HACF from the papillary muscle. For HACM isolation, ventricular tissue was grinded into very small fragments in PBS (pH 7.4) without enzymatic digestion. Red blood cells were removed by rinsing with PBS twice and debris was removed by passing through 40 mm cell strainer (Gibco-Life Technologies, Paisley, UK 
| Promoter accessibility assay
Chromatin accessibility was analysed using a commercially available Chromatin Accessibility Assay Kit (Abcam, Cat.Nr. ab185901) as described. 30 In short, HACM were treated with fluvastatin at 5 μmol L 
| Protein detection
Cells were lysed with PBS containing 0.1% Triton X-100 (Sigma). IL-33 protein in cell lysates and sST2 protein in cell culture supernatants were measured by a specific enzyme-linked immunosorbent assay (ELISA) (both R&D Systems, Minneapolis, MN, USA), as described by us previously. anti-Troponin I (abcam, Cambridge, UK, dilution 1:100) antibodies was performed as described. 27 The IL-33 fraction of the stained myocardial tissue was quantified using ImageJ software. Mean fluorescence intensity (MFI)
was compared between patients with or without statin treatment in order to determine the myocardial IL-33 content.
| Statistics
Values are expressed as mean ± SD. Data were compared by two- sST2 protein was detectable in cell culture supernatants of HACM in three from five tested donors and its secretion was reduced by fluvastatin at 5 μmol L −1 to 15% ± 2% after 24 h and to 29% ± 19% after 48 h of treatment compared to the respective controls (both P < 0.05). Fluvastatin also showed a trend towards downregulation of mRNA specific for sST2 in HACM in five donors tested (to 85% ± 24% after 24 h and to 62% ± 38% after 48 h as compared to the respective controls), but had no influence on the levels of ST2L mRNA (data not shown). 
|
| IL-33 is increased upon RhoA kinase inhibition and decreased upon RhoA activation
One of the most prominent geranylgeranylated protein is RhoA. 31 We tested if inhibition of ROCK, which is activated by active RhoA, RhoA activation results in changes in gene expression via activation of serum response factor (SRF). 32 Treatment of HACM with latrunculin B, which prevents SRF to localise to the nucleus, 33 at concentrations between 100 nmol L −1 and 1 μmol L −1 for 48 h led to a significant up to 15-fold increase of IL-33 protein levels (Figure 4C ).
T . Cells were permeabilised with PBS containing 0.1% Triton X-100, and IL-33 protein in cell lysates was determined as described in "Materials and methods". Values are given in x-fold of control, which was set as 1.0. Figure 4D ). We did not observe a significant change in the IL-33 promoter region after treatment with alendronate (1.4 fold of control, P = 0.6).
| Increased IL-33 expression in myocardial tissue of statin-treated patients
In order to support our in vitro data, we additionally examined IL-33 protein level in myocardial tissue from patients undergoing heart transplantation for end-stage HF under statin treatment or not treated with statins. As shown in Figure 5B , myocardial tissue from statin-treated patients express higher level of IL-33 protein compared with patients without statin treatment ( Figure 5A , P = 0.048). Quantification of MFI of the staining is shown in Figure 5C .
| DISCUSSION
In our study, we report a novel aspect of action for two widely ously published results from our group, which showed that pravastatin had no effect on apoptosis or the expression of components of the plasminogen system and osteoprotegerin in human cardiac, endothelial, or smooth muscle cells in vitro. 7, 8, 25, 36 In order to support our in vitro findings, we analysed IL- District 2) study concluded that higher-intensity statin use is associated with beneficial outcome in HF patients with ischaemic heart disease. 43 Interestingly, an overexpression of FFP synthase, the primary target of BPs, induced cardiac hypertrophy and HF in mice. 44 Furthermore, inhibition of FPP synthase attenuates hypertrophy in neonatal rat cardiomyocytes. 45 Therefore, both statins and BPs can act as anti-hypertrophic agents in different experimental models but the exact mechanisms are not clarified yet.
IL-33 is the most recently identified cytokine of the IL-1 family. 47, 48 We showed previously the intracellular expression of IL-33 in human cardiac myocytes and fibroblasts, and the release of IL-33 during necrosis of these cells. 27 Moreover, the "decoy" receptor for IL-33, sST2, was shown to have predictive value in patients with coronary artery disease and HF 16, [49] [50] [51] as well as in critically ill patients. 52 In our study presented here, we found that fluvastatin is able to reduce secretion of sST2 from human cardiac myocytes. Interestingly, a recent report showed that sST2 levels were attenuated after 12 months of atorvastatin treatment in patients with HIV. 53 However, rosuvastatin had no effect on the | 6129 levels of sST2 in patients with HF from the CORONA study though the change in sST2 levels was evaluated after 3 months of rosuvastatin treatment. 54 In the light of our in vitro data about down-regulation of sST2 secretion by fluvastatin, it would be warranted to evaluate a possible influence of long-term statin treatment on sST2 blood levels in clinical studies.
As an inflammatory mediator IL-33 plays a role in a variety of diseases such as bronchial asthma, inflammatory bowel diseases, and rheumatoid arthritis. 16 On the other hand, IL-33 antagonised prohypertrophic stimuli in rat neonatal cardiomyocytes and exhibited an anti-hypertrophic effect after transverse aortic constriction (TAC) in mice. 21 Furthermore, IL-33 protected rat neonatal cardiomyocytes from hypoxia-induced apoptosis and improved cardiac function in rats after experimental myocardial infarction. 22 IL-33 also attenuated ischaemia/reperfusion-induced myocardial injury in diabetic mice. 23 Recently, a cardioprotective role of the IL-33/ST2 system was shown in IL-33 knockout (IL-33 -/-) mice subjected to TAC, which exhibited exacerbated left ventricular hypertrophy, aggravated fibrosis, and impaired survival compared to wild-type littermates after TAC. 24 Therefore, IL-33 has been recognised as a cardioprotective cytokine.
In this context, it should be emphasised that the effects of statins on IL-33 expression in human cardiac cells were never studied before. Only one previous study showed that simvastatin induced IL-33 mRNA expression in human endothelial cells. 55 We further investigated, which mechanisms are responsible for the increase of IL-33. It was shown previously that the MVA pathway inhibitors simvastatin and ibandronate affect epigenetic regulation in cancer cells. 35 We demonstrate here that the promoter RhoA is a prominent geranylgeranylated protein, which has also been associated with the diseases of the cardiovascular system and bone. 31 Statins block the isoprenylation and thus the membrane targeting and functional activation of the Rho family member. 31 It has been shown that fluvastatin reduces RhoA in the membrane fraction of rat cardiac myocytes. 29 In spontaneously hypertensive rats simvastatin attenuated RhoA activity and myocyte hypertrophy. 57 The most important direct target of RhoA is ROCK. We therefore sus- It should be noted that the concentrations of statins and BPs as well as the components of the MVA pathway and specific inhibitors used in this study were in the same range as concentrations of these substances used in numerous other tissue culture studies. 3, [7] [8] [9] 14, 25, 29, 36 In conclusion, our study showed for the first time that IL-33
could be an important mediator of the pleiotropic effects of statins and BPs in human cardiac tissue. Considering potential safety issues, F I G U R E 6 Schematic representation of the downstream targets of the MVA pathway, depicting its various intermediates (blue), end products (green) and functional implications (yellow). Prenylation of RhoA with GGPP anchors RhoA to the plasma membrane, where it can be activated by signalling factors. Active RhoA activates ROCK, which triggers activation and translocation of SRF into the nucleus, where it represses the transcription of IL-33. Inhibitors used in this study are depicted in red: statins inhibit HMG-CoA-reductase; BPs inhibit GPP synthase and FPP synthase; perillic acid inhibits protein prenylation; latrunculin B prevents SRF activation; Y-27632 is a ROCK inhibitor. The RhoA activator U-46619 is depicted in green the feasibility and possible implications of the therapeutic modulation of IL-33 signalling, which is known to act cardioprotective, [21] [22] [23] [24] are currently discussed. 58 As statins and BPs represent widely used and standardised classes of drugs for primary and secondary prevention of cardiovascular disease, our results might have impact also in the clinical setting.
